JNCI Journal of the National Cancer Institute · 2012 · 90 citations · 49 references
MedicineCancer BiologyOncologyDrug DiscoveryMetastasisMolecular OncologyCancer ProgressionGrowth Factor SignalingMetastatic Breast CancerMetastatic Disease TreatmentMetastatic Signaling PathwaysTargeted TherapyBreast Cancer ProgressionCancer Metastasis MechanismsEpithelial-mesenchymal Transition MarkersMetastatic Breast Cancer TreatmentTransforming Growth Factor Beta Receptor SignalingTransforming Growth Factor Beta ReceptorsTransforming Growth Factor-beta SignalingTumor Metastasis Biology
BACKGROUND: Transforming growth factor beta (TGFβ), which is implicated in metastasis to various organs in breast cancer, is a potential target for new antitumor metastasis drugs. METHODS: To identify specific inhibitors of TGFβ receptor 1 (TGFβR1) in breast cancer metastasis, a virtual library of more than 400000 different compounds was screened by molecular docking modeling and confirmed with Smad-binding element luciferase and TGFβR1 kinase assays. Affymetrix GeneChip expression analysis of mRNA levels and real-time polymerase chain reaction were performed to determine expression changes of TGFβ-mediated, metastasis-associated genes in breast cancer cells after treatment with the small-molecule inhibitor YR-290. YR-290 was also examined for its effects on breast cancer migration, invasion, and metastasis using transwell and epithelial-to-mesenchymal transition (EMT) assays in vitro and three different mouse (BALB/c and NU/NU nude) models (n = 10 per group). Kaplan-Meier analyses were used to assess survival. All statistical tests were two-sided. RESULTS: YR-290 interacted with the kinase domain of TGFβR1, abrogated kinase activity (half maximal inhibitory concentration = 137nM, 95% confidence interval = 126.4 to 147.6nM) and inhibited the TGFβ-mediated downstream signaling pathway and metastasis-associated genes in breast cancer cells. YR-290 inhibited TGFβ-modulated breast cancer cell migration and invasion. In tumor metastasis mouse models, YR-290 almost completely blocked cancer metastasis. Numbers of lung tumor nodules of mice treated with 1mg/kg and 5mg/kg YR-290 were reduced by 74.93% (95% confidence interval = 61.45% to 88.41%) and 94.93% (95% confidence interval = 82.13% to 100%), respectively, compared with control mice. Treatment with YR-290 also statistically significantly prolonged the survival of tumor-bearing mice. CONCLUSIONS: YR-290 is a novel inhibitor of tumor metastasis that works by blocking TGFβ signaling pathways.
49
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Genes that mediate breast cancer metastasis to lung
Andy J. Minn, Gaorav P. Gupta, Peter M. Siegel et al. · Nature · 2005 · 3K citations · Full text
Gareth J. Inman, Francisco José Nicolás, James F. Callahan et al. · Molecular Pharmacology · 2002 · 1.7K citations
TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation
Yi Tang, Xiangwei Wu, Weiqi Lei et al. · Nature Medicine · 2009 · 1.2K citations · Full text